Quote:

---

t’s interesting that such a small jump in fibrotic area in the chart you attached, which appears to me to a jump from 5.5% to about 6.5% fibrotic area, would result in a 3.7 fold chance of dying (CDE to CDE+MVC).

---

It looks like 7.5% and 5.5% to me. That study was to test progression to liver cancer and most likely the deaths were caused by that rather than NASH.

Maraviroc runs around 80% receptor occupancy and a 50.8% effectiveness in HIV treatment at best. With leronlimab at 350mg you have an 85% receptor occupancy and 81% effectiveness in HIV. Leronlimab at 700mg you have 100% receptor occupancy and 92% effectiveness.

One question is, if maraviroc and leronlimab 350mg receptor occupancy are so close why would there be such a wide divergence in effectiveness? Maraviroc uses a shape change in the CCR5 receptor to keep HIV from binding. It could be in some cases that there isn't enough of a shape change and HIV binds anyway. This also may possibly occur with natural ligands. This would definitely show a major advantage over maraviroc in any treatment.